Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell LymphomaMichael R. Bishop, Jason R. Westin, Michael Dickinson et al.|New England Journal of Medicine|2021Cited by 532
Abstract P2-01-24: Immune activation of tumor cells and microenvironment as assessed by PD-L1 expression and interferon gamma signaling predict long term disease-free and overall survival: Results of the prospective randomized neoadjuvant ABCSG 34 trialUlrike Heber, Zsuzsanna Bagó-Horváth, Richard Greil et al.|Clinical Cancer Research|2025Cited by 0